# Exploring the potential link between mRNA COVID-19 vaccinations and cancer: A case report with a review of haematopoietic malignancies with insights into pathogenic mechanisms

## TL;DR

This paper explores a possible link between mRNA COVID-19 vaccines and blood cancers, based on a case report and review of existing literature.

## Contribution

The novelty lies in presenting a case of ALL/LBL post-vaccination and reviewing potential mechanisms linking modRNA vaccines to hematopoietic malignancies.

## Key findings

- A case of ALL and LBL was observed following a second dose of the Pfizer/BioNTech vaccine.
- modRNA vaccines may affect bone marrow and blood-forming organs, potentially triggering neoplastic processes.
- Current evidence suggests a possible association between modRNA vaccines and hematopoietic cancers.

## Abstract

This article investigates the potential association between modified mRNA (modRNA) COVID-19 vaccinations and the development of haematopoietic cancers. We present a case involving a healthy, young, athletic woman who developed acute lymphoblastic leukaemia (ALL) and lymphoblastic lymphoma (LBL) following her second dose of the Pfizer/BioNTech COVID-19 vaccine (Comirnaty®). This case is part of an expanding body of literature documenting similar occurrences after modRNA vaccinations, which we critically examine. Emerging evidence suggests that the biodistribution and persistence of modRNA, facilitated by lipid nanoparticles, can affect various tissues and organs, including the bone marrow and other blood-forming organs. Notably, modRNA vaccines exhibit a particular affinity for the bone marrow, potentially influencing the immune system at multiple levels and triggering both autoimmune disorders and neoplastic processes. In this article, we assess the risk of developing haematopoietic cancers post-modRNA vaccination based on current scientific literature and explore the reported potential genetic and molecular mechanisms involved in disease pathogenesis. By integrating clinical observations and current research, we aim to provide valuable insights into the potential carcinogenic outcomes associated with modRNA vaccination.